Blood dendritic cells in patients with acute lymphoblastic leukaemia

Mami, Naira Ben; Mohty, Mohamad; Chambost, Hérvè; Gaugler, Béatrice; Olive, Daniel

doi:10.1111/j.1365-2141.2004.04989.x

Cited by 29 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Decreased numbers of DC could not be explained by mere bone marrow dysfunction owing to infiltration of leukemic blast cells, as we were unable to document a correlation between DC numbers and other myeloid cell numbers such as neutrophils and monocytes. Our data are in accordance with observations published by Mami et al, 14 who detected normal numbers of DC in adult and few pediatric pT-ALL patients but significantly reduced DC numbers in pB-ALL patients. This group was able to demonstrate apparently normal cytokine-secreting function of DC in T-ALL patients, which is paralleled by our findings of unchanged phenotypic characteristics of DC in pediatric pT-ALL patients.…”

Section: Discussionsupporting

confidence: 83%

“…Interestingly, Mami et al 14 were unable to generate either mDC or pDC from CD34 þ precursor cells from pB-ALL patients. In our studies, lack of mDC was significantly associated with aberrant expression of myeloid markers CD13, CD33, and myeloperoxidase on Bprecursor leukemic blasts.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have demonstrated numerical as well as functional abnormalities of DC in patients with cancer (for review see Gabrilovich 18 ), in particular acute leukemias. 11,14 Among functional defects, there are decreased expression of MHC or co-stimulatory molecules, 19,20 insufficient T-cell stimulatory capacity 20,21 and accumulation of immature DC in cancer patients. 21 As patients with ALL display particularly poor antitumor immune responses, 6 we sought to investigate the DC compartment in pediatric patients.…”

Section: Discussionmentioning

confidence: 99%

“…Defects in DC function have been demonstrated in several other diseases of either viral infection (chronic hepatitis C, 9 HIV infection 10 ) or leukemic malignancies (acute myeloid leukemia, 11 chronic myelogenous leukemia, 12 hairy cell leukemia 13 ). Recently, Mami et al 14 showed reduced DC in a group of adult and pediatric patients with B-cell precursor ALL. Thus, defects in dendritic cells may impact on poor antileukemia immune responses in patients with childhood ALL.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients

et al. 2006

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) cells are particularly poor at generating anti-leukemia immunity, despite residing in lymphoid organs. To assess a potential role of dendritic cells (DC) in poor anti-leukemia immunity, we analyzed peripheral blood DC in 55 pediatric ALL patients at the time of initial diagnosis and 19 age-matched healthy controls. Dendritic cells were identified by their expression of HLA-DR, lack of B, T, NK, and monocyte markers, and expression of CD11c (myeloid DC(mDC)) or BDCA-2 (plasmacytoid DC(pDC)) using flow cytometry. We found that in children with B-lineage ALL, numbers of both mDC and pDC were significantly reduced (P ¼ 0.0001). In contrast, T-lineage ALL patients showed normal pDC and significantly elevated mDC (P ¼ 0.003) levels, with normal expression of HLA-DR and co-stimulatory molecules. A decrease in DC could not be explained by general impairment of myelopoiesis, as we could not demonstrate a correlation of DC numbers with granulocyte/monocyte numbers in patients with B-lineage ALL. However, aberrant expression of myeloid surface markers on leukemic blasts was frequent in patients lacking myeloid DC indicating a potential block of DC differentiation. Thus, depletion of DC in B-lineage ALL patients may contribute to poor anti-leukemia immune responses.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Indeed, a decrease in the blood MDC and PDC frequencies has been described during the course of various kinds of hematological malignancies (Mohty et al, 2002;Ratta et al, 2002;Boissel et al, 2004;Mami et al, 2004). In these cases, low DC counts might be due to an alteration of ''dendritopoiesis'' during the disease progression.…”

Section: Discussionmentioning

confidence: 96%

Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor

Charles

Domizio

Salameire

et al. 2010

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Dendritic cells (DCs) are central cells in the development of antitumor immune responses, but the number and function of these cells can be altered in various cancers. Whether these cells are affected during the development of melanoma is not known. We investigated the presence, phenotype, and functionality of circulating myeloid DCs (MDCs) and plasmacytoid DCs (PDCs) in newly diagnosed melanoma patients, compared to controls. The frequencies of PDCs and MDCs were equivalent in melanoma patients as compared with normal subjects. Both circulating DC subsets were immature, but on ex vivo stimulation with R848 they efficiently upregulated their expression of costimulatory molecules. We found that circulating DCs from melanoma patients and controls displayed similar pattern of expression of the chemokine receptors CXCR3, CXCR4, CCR7, and CCR10. Strikingly, PDCs from melanoma patients expressed higher levels of CCR6 than control PDCs, and were able to migrate toward CCL20. Further data showed that CCR6-expressing PDCs were present in melanoma primary lesions, and that CCL20 was produced in melanoma tumors. These results suggest that PDCs and MDCs are functional in melanoma patients at the time of diagnosis, and that CCL20 may participate to their recruitment from the blood to the tumor.

show abstract

Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia

Rolf

Smolen

Kariminia

et al. 2017

Cancer Immunol Immunother

View full text Add to dashboard Cite

Several retrospective studies in children with B cell precursor (BCP) acute lymphoblastic leukemia (ALL) provided clinical evidence that higher absolute lymphocyte counts (ALC) early into treatment significantly correlated with improved relapse-free and overall survival. It still remains unknown, however, whether the predictive role of higher ALCs reflects general bone marrow recovery or a more specific attribute of immune function. To investigate this question, we implemented a prospective observational cohort study in 20 children with BCP ALL on day 29 (D29) of induction chemotherapy and immunophenotyped their lymphoid (T, B and natural killer cells) and myeloid (neutrophils, monocytes, dendritic cells) compartments. In a first evaluation of a cohort treated with Children's Oncology Group-based induction chemotherapy, the immune cell compartments were differentially depleted at D29. Neither gender, risk status, minimal residual disease, nor bone marrow recovery markers correlated with D29 ALC. In contrast, both CD3 T cell and dendritic cell compartments, which did not correlate with age, significantly correlated with D29 ALC (p < 0.0001). In addition, subset complexity of cellular immune compartments was preserved at D29. This study reveals that D29 ALC significantly correlates with distinct immune cell compartments but not with bone marrow recovery markers, suggesting that higher D29 ALCs may contribute to leukemia control by inducing specific host immune activity.

show abstract

Blood dendritic cells in patients with acute lymphoblastic leukaemia

Cited by 29 publications

References 14 publications

Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients

Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients

Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor

Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia

Contact Info

Product

Resources

About